Tracking Cancer Drugs in Living Cells by Thermal Profiling of the Proteome
Mikhail M. Savitski, Friedrich B. M. Reinhard, Holger Franken, Thilo Werner, Maria Fälth Savitski, Dirk Eberhard, Daniel Martinez Molina, Rozbeh Jafari, Rebecca Bakszt Dovega, Susan Klaeger, Bernhard Kuster, Pär Nordlund, Marcus Bantscheff, Gerard Drewes.
Science 3 October 2014, Vol. 346, no. 6205
This paper demonstrates a new approach for the unbiased measurement of drug-target binding, illustrating the interaction of anticancer drugs with human leukemia cells. By measuring the changes in the thermal profiles or "melting points" for over 7,000 proteins, the authors were able to identify over 50 targets for the kinase inhibitor, staurosporine. Additionally, the heme biosynthesis enzyme ferrochelatase was inhibited, suggesting this as a cause for the phototoxicity observed with vemurafenib and alectinib. It is expected that thermal proteome profiling can be extended to membrane proteins as well as tissues from animal studies or clinical biopsies. In a press release on the study, Bernhard Kuster of Technische Universität München and the German Cancer Research Center said, "We hope to use this method in the future to explain or even predict many adverse effects." |
|